Stellar analyzing high placebo response rate in pilot study

Stellar Pharmaceuticals (OTCBB:SLXCF) believes that an “anomalously high placebo response rate may be a possible reason for the primary efficacy endpoints … not having been met” in Watson Pharma’s (NYSE:WPI) pilot study of Stellar’s Uracyst drug for the treatment of interstitial cystitis/painful bladder syndrome (IC/PBS) in the U.S. The company said it plans to continue [...]

Stellar gets Uracyst patents in China and U.S.

Stellar Pharmaceuticals (OTCBB: SLXCF) has been issued patents for Uracyst, one of its lead products for the treatment of interstitial cystitis/painful bladder syndrome, by both the Chinese Patent Office and the U.S. Patent and Trademark Office. The Chinese patent covers pharmaceutical compositions that comprise the greater and superior dosage size of chondroitin sulfate, and the [...]